Primary cutaneous plasmacytoma: treatment with intralesional tumour necrosis factor-alpha.
We report a case of primary multiple cutaneous plasmacytomas, without underlying multiple myeloma, treated with intralesional tumour necrosis factor-alpha (TNF-alpha). A marked reduction in tumour size, with no significant adverse effects, suggests that intralesional TNF-alpha is an effective treatment for non-solid malignant tumours. Extramedullary plasmacytoma, especially involving the skin as a primary site, has rarely been reported in the English literature. We describe the ninth reported case of multiple cutaneous plasmacytomas without underlying multiple myeloma. Intralesional tumour necrosis factor-alpha (TNF-alpha) was used to treat this disease and its anti-tumour effect quantitatively evaluated by comparing the tumour size and histological change before and after treatment.
Tsuboi
R
R
Department of Dermatology, Juntendo University School of Medicine, Tokyo, Japan.
Morioka
R
R
Yaguchi
H
H
Shimokawa
R
R
Inaba
M
M
Ogawa
H
H
D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha